Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study

Aging Clinical and Experimental Research

Volumn 28, Issue 6, 2016, Pages 1251-1257

  Perna, Simone ^a   Guido, Davide ^a   Bologna, Chiara ^a   Solerte, Sebastiano Bruno ^a   Guerriero, Fabio ^a   Isu, Antonio ^a   Rondanelli, Mariangela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Diabetes; Elderly; Fat mass; Liraglutide; Muscle; Obesity; Sarcopenia

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN;

AGED; AGING; ARM; ARTICLE; ASSESSMENT OF HUMANS; BODY COMPOSITION; BODY FAT; BODY MASS; CASE STUDY; CLINICAL ARTICLE; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT FREE MASS; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEG; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SARCOPENIA; SKELETAL MUSCLE; SKELETAL MUSCLE INDEX; TREATMENT DURATION; ANALOGS AND DERIVATIVES; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; BIOMARKERS; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES; SARCOPENIA;

EID: 84953376222     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-015-0525-y     Document Type: Article

References (32)

1. Han TS, Wu FCW, Lean MEJ (2003) Obesity and weight management in the elderly: a focus on men. Best Pract Res Clin Endocrinol Metab 27:509–525
2. Drucker DJ, Philippe J, Mojsov S et al (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci 84:3434–3438
3. Stoffers DA, Kieffer TJ, Hussain MA et al (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741–748
4. Doyle ME, Egan JM (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113:546–593
5. Buteau J (2008) GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diab Metab 34:73–77
6. Werner U, Haschke G, Herling AW et al (2010) Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Rev Regulat Peptides 164:58–64
7. Nikolaidis LA, Elahi D, Hentosz T et al (2004) Recombinant glucagonlike peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955–961
8. Zhao T, Parikh P, Bhashyam S et al (2006) Direct effects of glucagonlike peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317:1106–1113
9. Basu A, Charkoudian N, Schrage W et al (2007) Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293:E1289–E1295
10. Nyström T (2008) The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res 40:593–606
11. Chai W, Dong Z, Wang N et al (2012) Glucagon-like peptide. Recruits microvasculature and increases glu cose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61:888–896
12. Luque MA, González N, Márquez L et al (2002) Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 173:465–473
13. Acitores A, Gonzalez N, Sancho V et al (2004) Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J Endocrinol 180:389–398
14. Gonzalez N, Acitores A, Sancho V et al (2005) Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126:203–211
15. Green CJ, Henriksen TI, Pedersen BK et al (2012) Glucagon-like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PloS One 7:e44284
16. Washburn RA, Smith KW, Jette AM et al (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46:153–162
17. Janssen I, Baumgartner RN, Ross R et al (2004) Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 159:413–421
18. Baumgartner RN, Koehler KM, Gallagher D et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763
19. Lu N, Sun H, Yu J et al (2015) Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PloSone 10:e0132744
20. Cetrone M, Mele A, Tricarico D (2104) Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr diabetes rev 10:231–237
21. Green CJ, Henriksen TI, Pedersen BK et al (2012) Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PloS One 7:e44284
22. Yamamoto K, Amako M, Yamamoto Y et al (2013) therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury. Biomed Res Int 2013:315848
23. Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163–1172
24. Inoue K, Maeda N, Kashine S et al (2011) Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 10:109
25. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84–90
26. Li CJ, Yu Q, Yu P et al (2014) Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol 13:36
27. Wannamethee SG, Shaper AG, Lennon L et al (2007) Decreased muscle mass and increased central adiposity are independently related to mortality in older men. Am J Clin Nutr 86:1339–1346
28. Bode BW, Brett J, Falahati A et al (2011) Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother 9:423–433
29. Peters KR (2013) Liraglutide for the treatment of type 2 diabetes: a clinical update. Am J Ther 20:178–188
30. Elashoff M, Matveyenko AV, Gier B et al (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150–156
31. Knezevich E, Crnic T, Kershaw S et al (2012) Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm 69:386–389
32. Korkmaz H, Araz M, Alkan S et al (2015) Liraglutide-related cholelithiasis. Aging Clin Exp